Terumo Blood and Cell Technologies (Terumo BCT) has announced funding support for a multi-center clinical trial aimed at reducing complications from acute chest syndrome (ACS) in adult patients with sickle cell disease (SCD). Researchers at Henri Mondor University Hospital in France will lead the trial, known as ARCAD, to evaluate the efficacy and safety of…more
Terumo Blood and Cell Technologies (Terumo BCT) has announced a strategic partnership with Terumo Medical Products (Hangzhou) Co. Ltd., investing in a production facility in Qiantang District, Hangzhou. This initiative aims to provide locally made medical products for the Chinese market, including devices used to collect and separate blood and cells. The launch ceremony, themed…more
Lakewood-based Terumo Blood and Cell Technologies (Terumo BCT) has announced the establishment of its new Global Therapy Innovations business unit. The unit aims to integrate disease expertise throughout the patient journey, from cell collections to therapy delivery, and is led by Veerle d’Haenens, general manager, Global Therapy Innovations. The initiative intends to enhance standards of…more
Terumo Blood and Cell Technologies (Terumo BCT) is scaling up its offerings in Latin America to promote the adoption of automated manufacturing for cell and gene therapy companies in Brazil, Colombia and Mexico. The company aims to enhance efficiency and cost-effectiveness in the manufacturing process for regional firms. Cell and gene therapies are rapidly advancing…more
Terumo Blood and Cell Technologies (Terumo BCT), based in Lakewood, has launched the Reveos Automated Blood Processing System in the United States, aimed at improving blood and platelet supply efficiency for blood centers. The system has been used globally for over a decade in more than 50 countries. Carter BloodCare in Texas is set to…more
Terumo Blood and Cell Technologies (Terumo BCT) and the Sanquin Blood Supply Foundation, the Netherlands national blood supply authority, have signed a 10-year agreement to implement Lakewood-based Terumo BCT’s Reveos Automated Blood Processing System across Sanquin’s blood processing facilities. Sanquin, known for its pioneering buffy coat process for producing blood components, will transition to the…more
Aclarion Inc. announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. The randomized controlled trial is studying 202 patients with low back pain lasting more than one year and will compare outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation. Nociscan was selected for use in the…more
Aclarion Inc. announced the launch of a program aimed at developing a statewide network of providers in New Jersey to utilize its AI technology, Nociscan, for the personal injury and workers compensation sectors. Dr. Justin Kubeck, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, N.J., will lead this initiative to…more
Westminster-based ARCA Biopharma Inc. (NASDAQ: ABIO) announced the completion of its merger with Oruka Therapeutics Inc. The merger follows ARCA’s successful receipt of stockholder approval for all related proposals at a special meeting on Aug. 22, 2024. The combined company will operate as “Oruka Therapeutics Inc.”, with its common stock to be traded on Nasdaq…more
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology firm, has announced the launch of the multi-center Clinical Utility and Economic (CLUE) Trial. The trial aims to quantify the frequency with which surgeons alter their original treatment plans after receiving data from Aclarion’s proprietary Nociscan technology. In the CLUE Trial, surgeons will determine their…more
ARCA Biopharma Inc. (Nasdaq: ABIO), a Westminster company known for its focus on genetically targeted therapies for cardiovascular diseases, has announced a significant update regarding its corporate strategy and planned merger with Oruka Therapeutics Inc. As part of the merger, ARCA plans to divest its legacy technology and intellectual property, including assets related to Gencaro…more
Aclarion Inc., a Broomfield-based health care technology firm, has announced the extension of its commercial agreement with the prestigious London Clinic. This contract expansion signifies increased payment for each Nociscan use, efforts to secure payer coverage decisions from top private health insurers, and strategies to enhance access to Nociscan within the greater London market. Aclarion,…more